0
Skip to Content
Affordable.Skin
Find Comparables
Shop
Resources
Contact
About
Chatbot Test
Affordable.Skin
Find Comparables
Shop
Resources
Contact
About
Chatbot Test
Find Comparables
Shop
Resources
Contact
About
Chatbot Test
Shop La Roche-Posay Effaclar K Plus Face Cream
61-GEpTuCnL.jpg Image 1 of 12
61-GEpTuCnL.jpg
81JJHuQ65+L.jpg Image 2 of 12
81JJHuQ65+L.jpg
819BSHMz2OL.jpg Image 3 of 12
819BSHMz2OL.jpg
51fzbDehccL.jpg Image 4 of 12
51fzbDehccL.jpg
61qYmUnzNTL.jpg Image 5 of 12
61qYmUnzNTL.jpg
714Yag-RFUL.jpg Image 6 of 12
714Yag-RFUL.jpg
81LdlrZFfFL.jpg Image 7 of 12
81LdlrZFfFL.jpg
715al+hxXwL.jpg Image 8 of 12
715al+hxXwL.jpg
71xANHO0lCL.jpg Image 9 of 12
71xANHO0lCL.jpg
41ZBR8W+0eL.jpg Image 10 of 12
41ZBR8W+0eL.jpg
311VDxXNPzL.jpg Image 11 of 12
311VDxXNPzL.jpg
51DioMbaq+L.jpg Image 12 of 12
51DioMbaq+L.jpg
61-GEpTuCnL.jpg
81JJHuQ65+L.jpg
819BSHMz2OL.jpg
51fzbDehccL.jpg
61qYmUnzNTL.jpg
714Yag-RFUL.jpg
81LdlrZFfFL.jpg
715al+hxXwL.jpg
71xANHO0lCL.jpg
41ZBR8W+0eL.jpg
311VDxXNPzL.jpg
51DioMbaq+L.jpg

La Roche-Posay Effaclar K Plus Face Cream

$0.01

Product Description

This skincare product is designed for adult imperfection-prone skin, particularly for women. It is well tolerated, allergy tested, and non-comedogenic, making it suitable for sensitive skin. The product has been tested on oily imperfection-prone skin to ensure its effectiveness.

Quantity:
Add To Cart

Product Description

This skincare product is designed for adult imperfection-prone skin, particularly for women. It is well tolerated, allergy tested, and non-comedogenic, making it suitable for sensitive skin. The product has been tested on oily imperfection-prone skin to ensure its effectiveness.

Product Description

This skincare product is designed for adult imperfection-prone skin, particularly for women. It is well tolerated, allergy tested, and non-comedogenic, making it suitable for sensitive skin. The product has been tested on oily imperfection-prone skin to ensure its effectiveness.

Affordable.Skin

Terms of Use

Privacy Policy

Sign up with your email address to receive news and updates.

Thank you!